This latest study doesnt mean we throw out Ozempic and Rybelsusit means we get smarter, more cautious, and more transparent
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapeutic agents, as they stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving glycemic control with a low risk of hypoglycemia [2]
That said, a major barrier to achieving widespread adoption lies in affordability according to our survey, 45% of current patients cite cost as one of the primary reasons for discontinuing their medication
Splitting the same total weekly dose into multiple injections doesn't save money
The weight loss timeline also correlates with improvements in quality of life metrics that go beyond the scale
Solid phase synthesis of hydrogen bond surrogate derived alpha-helices: resolving the case of a difficult amide coupling